|
EP3583949A1
|
|
Toll-like receptor 2 (tlr2) antagonists for the treatment of ovarian cancer
|
|
WO2018099614A1
|
|
Methods and compositions for the treatment of myelodysplastic syndrome
|
|
US2016355603A1
|
|
Methods and compositions for the treatment of pancreatic cancer
|
|
EP2722342A1
|
|
Methods and compositions for the treatment of pancreatic cancer
|
|
GB201205633D0
|
|
Toll-like receptor 2 binding epitope and binding members thereto
|
|
IE20090514A1
|
|
Humanised antibodies and uses therof
|
|
GB0911664D0
|
|
Compounds and methods for the suppression of an immune response
|
|
CA2693237A1
|
|
Anti-toll-like receptor 2 antibodies for use in the treatment of cardiac inflammatory conditions
|
|
CN101730545A
|
|
Compounds and methods for the treatment of renal disease
|
|
CA2691784A1
|
|
Composition and method for treatment of autoimmune disease
|
|
US2010143336A1
|
|
Toll-like receptor binding epitope and compositions for binding thereto
|
|
AU2007313151A1
|
|
Compositions and methods for modulating TLR14 activity
|
|
AU2006231724A1
|
|
Assays for determining compounds which modulate TRAM phosphorylation
|
